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Abstract We have introduced eleven point mutations into the
human vitamin D receptor by site-directed mutagenesis in order
to identify some of the amino acid residues that are important for
ligand binding. The amino acid residues Ser225, His229, Asp232,
Val234, Ser235, Tyr236, Ser237, Lys240, Ile242, Lys246 (helix
3), and Ser275 (helix 5) of the human vitamin D receptor were
substituted by alanine. We report here that His229, Asp232, and
Ser237 have an important role in the binding of calcitriol. In
addition, the amino acid residues Tyr236 and Ser275 also seem
to participate in the ligand binding process.
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1. Introduction
Human vitamin D receptor (hVDR) belongs to the super-
family of steroid receptors. These receptors are nuclear tran-
scription factors that are known to have direct genomic ef-
fects. They regulate gene expression in response to binding of
their speci¢c ligands. The binding changes the conformation
of the receptors which enables transactivation. This can result
in either activation or repression of gene transcription [1^4].
Crystal structures of the unliganded ligand-binding domain
(LBD) of human retinoid X receptor-K (hRXRK), and the
liganded LBDs of human retinoic acid receptor-Q (hRARQ),
rat thyroid hormone receptor-K (rTRK), human estrogen re-
ceptor (hER), and human progesterone receptor (hPR) have
recently been determined [5^9]. The crystal cultures of the
liganded hRARQ, rTRK, hER, and hPR have revealed that
in all these cases the speci¢c ligands have multiple distinct
contact sites within their receptors. All contact sites are posi-
tioned in the ligand binding pocket, which is located between
helices 5, 6, 11, and 3. Several mutational studies and molec-
ular modeling studies have also indicated that in steroid re-
ceptors helices 3, 5, and 11 are important for ligand binding
[10^14]. Furthermore, Klaholz et al. have recently studied the
binding of 9-cis retinoic acid and the synthetic ligand BMS961
to hRARQ by X-ray crystallography and reported that inter-
actions occurred between those ligands and helices 3 and 5
among other segments of the hRARQ [15].
Based on this information we have produced 11 distinct
mutated clones of hVDR by site-directed mutagenesis.
Ten mutated amino acid residues are located in the putative
helix 3 of the vitamin D receptor and one in the putative helix
5. The abilities of 1K,25-dihydroxy[26,27-methyl-
3H]cholecalciferol and its synthetic analog [26,27-14C2]-
MC1288 to bind to the in vitro translated wild-type and mu-
tated hVDRs were measured and the results were compared
with each other to determine whether the mutations in£u-
enced ligand binding. We also used partial proteolytic diges-
tion of in vitro translated hVDR to gain an insight into the
ligand-induced conformations of the wild-type and mutated
receptors. Finally, molecular modeling was used to ¢nd out
the putative positions of the mutated amino acid residues with
respect to their interactions with the ligands.
2. Materials and methods
2.1. Site-directed mutagenesis
To ¢nd the contact sites of calcitriol in the hVDR, the prospective
amino acid residues were chosen for site-directed mutagenesis by com-
paring their hydropathy indexes [16] and the amino acid sequences of
the hVDR with the known 3-D structures of hRARQ, rTRK, hER,
and hPR [6^9]. The mutated amino acid residues of hVDR and the
known contact sites of hRARQ, hER, hPR, and rTRK are shown in
Fig. 1. The cDNA of hVDR was subcloned into expression vector
pSP65 and used as a template for site-directed mutagenesis by Quick-
Change Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK).
Eleven clones of mutated hVDR were produced by changing the ami-
no acid residues Ser225, His229, Asp232, Val234, Ser235, Tyr236,
Ser237, Lys240, Ile242, Lys246, and Ser275 separately into alanines
as described by the manufacturer. The vectors incorporating the de-
sired mutations were then transformed into Epicurian coli XL1-Blue
supercompetent cells. The cDNAs of the clones were puri¢ed by Qia-
gen Plasmid Kit (Qiagen, Valencia, CA, USA) and sequenced com-
pletely to ensure that no other base changes were produced.
2.2. Binding of radioactive calcitriol and MC1288 to in vitro translated
wild-type and mutated hVDRs
The wild-type and mutated hVDRs were prepared in vitro by the
coupled wheat germ extract system with either wild-type or modi¢ed
hVDR cDNA inserted into plasmid pSP65 as described by the man-
ufacturer (Promega, Madison, WI, USA). The binding of radioactive
calcitriol or MC1288 to wild-type and mutated hVDRs was assessed
by one point analysis. Five-Wl aliquots of mixtures containing in vitro
translated unlabeled hVDRs (25 Wg of total protein) in a ¢nal volume
of 20 Wl were treated for 30 min at 22‡C with 0.5 nM 1K,25-dihy-
droxy[26,27-methyl-3H]cholecalciferol (179 Ci/mmol, Amersham In-
ternational, Buckinghamshire, UK) or 5 WM [26,27-14C2]-MC1288
(a gift from Leo Pharmaceutical Products, Ballerup, Denmark) di-
luted with ethanol. Unbound radioactivity was removed by treatment
with dextran-coated charcoal and the bound radioactivity was meas-
ured by scintillation counting. The experiment was repeated three
times and the results were corrected for background. For Scatchard
analysis, 5 Wl aliquots of in vitro translated receptor proteins (25 Wg of
total protein) in a ¢nal volume of 20 Wl were treated as above with
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0.005^5 nM 1K,25-dihydroxy[26,27-methyl-3H]cholecalciferol. Statisti-
cal analysis was performed by the SPSS (6.1.1.) program.
2.3. Digestion of in vitro translated hVDRs
L-[35S]Methionine (s 1000 Ci/mmol, Amersham International,
Buckinghamshire, UK) labeled wild-type and mutated hVDRs were
prepared in vitro by the coupled wheat germ extract system as de-
scribed above. Five-Wl aliquots of mixtures containing the in vitro
translated hVDRs in a ¢nal volume of 20 Wl were pre-incubated
with 1 WM of non-radioactive calcitriol or MC1288 (a gift from Leo
Pharmaceutical Products, Ballerup, Denmark) diluted with ethanol
for 30 min at 22‡C before exposing them to partial proteolytic diges-
tion by 25 Wg/ml trypsin (EC 3.4.21.4) (Sigma, St. Louis, MO, USA)
for 10 min at 22‡C. The reaction was stopped by adding 4 Wl of 6-fold
SDS-loading bu¡er and boiling for 5 min. The digestion products
were analyzed by SDS-polyacrylamide gel electrophoresis and auto-
radiography.
2.4. Molecular modeling
The ligand binding domain of hRARQ complexed with all-trans
retinoic acid (pdb entry 2lbd) was used to locate the mutated amino
acid residues of hVDR and their putative positions with respect to the
ligand binding pocket. With molecular modeling, helices 3 and 5 of
hRARQ were replaced by helices 3 and 5 of hVDR. The ¢gure was
constructed with the program SETOR [17].
3. Results and discussion
The binding studies revealed that changing the amino acid
residues Ser225, Val234, Ser235, Lys240, Ile242, and Lys246
separately into alanines did not markedly a¡ect the ability of
the radioactive calcitriol to bind to the mutated receptor com-
pared with the wild-type hVDR (Fig. 2a). However, when
either His229, Asp232, or Ser237 were replaced by alanine,
the binding a⁄nities decreased signi¢cantly indicating that
these amino acid residues are important for ligand binding
(Table 1). Furthermore, the amino acid residues Tyr236 and
Ser275 also seem to participate in the ligand binding process.
These results suggest that the putative helix 3 of hVDR and,
especially the central part of it, is an important structural
element in the formation of the ligand binding pocket. In
addition, the putative helix 5 of hVDR seems to have a role
in the ligand binding.
We and others have previously reported that ligand binding
changes the conformation of hVDR resulting in resistance
against partial proteolytic digestion [12,13,18^20]. In the
present study, we utilized this feature of the receptor to obtain
information on the conformations of the mutated receptors.
When the mutated receptors were exposed to partial proteo-
lytic digestion, the substitutions Ser225Ala, Val234Ala,
Ser235Ala, Lys240Ala, Ile242Ala, and Lys246Ala did not
markedly change the protective e¡ect of ligand binding
against partial proteolysis compared with that of the wild-
type hVDR (Fig. 3a). The substitution Ser275Ala decreased
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Fig. 1. Sequence alignments of helix 3 regions of hVDR, hRARQ,
hER, hPR, and rTRK. (*) Target amino acid residues for site-di-
rected mutagenesis; (b) known contact amino acid residues in hRARQ,
hER, hPR, and rTRK for ligand binding.
Fig. 2. Binding of radioactive calcitriol (a) and MC1288 (b) to in vi-
tro translated wild-type and mutated hVDRs. Wild-type and mu-
tated hVDRs were treated for 30 min at 22‡C with 0.5 nM 1K,25-
dihydroxy[26,27-methyl-3H]cholecalciferol or [26,27-14C2]-MC1288.
Unbound radioactivity was removed by treatment with dextran-
coated charcoal and the bound radioactivity was measured by scin-
tillation counting. Means þ S.E. are presented.
Table 1
Comparison of Kd values of the wild-type and mutated hVDRs
hVDRs Kd of calcitriol (nM)a
Wild type 1.02 þ 0.02
Ser225Ala 1.12 þ 0.03
His229Ala 26.75 þ 0.13
Asp232Ala 29.54 þ 0.05
Val234Ala 1.46 þ 0.03
Ser235Ala 1.42 þ 0.03
Tyr236Ala 3.50 þ 0.08
Ser237Ala 23.29 þ 0.16
Lys240Ala 1.37 þ 0.03
Ile242Ala 1.22 þ 0.01
Lys246Ala 1.92 þ 0.03
Ser275Ala 5.29 þ 0.09
aMean þ S.E.
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the ligand dependent protection, but the entire LBD of the
hVDR was still visible in the gel, indicating that ligand bind-
ing had occurred and changed the conformation of the recep-
tor. The substitutions His229Ala, Asp232Ala, Tyr236Ala, and
Ser237Ala, however, resulted in complete degradation of the
LBD in the presence of the ligand. This suggests that either no
ligand binding had occurred or that the ligand induced con-
formational changes of the receptors were markedly di¡erent
from those of the wild-type hVDR resulting in sensitivity to
partial proteolytic digestion. Our study con¢rms previous re-
ports on the occurrence of correlation between ligand binding
and the resistance of hVDR to partial proteolysis [12,13,18^
20]. Furthermore, our point mutation results con¢rm the mo-
lecular modeling results of Wurtz et al. on the importance of
Ser237 and Ser275 for the binding of calcitriol [14]. Based on
these data it is reasonable to suggest that the loss of ligand
dependent protection with the indicated mutants resulted
from decreased ability of the ligand to bind to the hVDR.
Molecular modeling supported these results. From Fig. 4 it
can be observed that the amino acid residues His229, Tyr236,
and Ser237 are positioned so that they can readily interact
with the ligand. If the ligand is in a more bent conformation,
like in the 6-s-trans conformation of calcitriol [21], the inter-
action may also occur with Asp232. Tyr236 and Ser275, in
turn, are located close enough for potential interactions, but
the substitutions Tyr236Ala and Ser275Ala only partially
blocked the ligand binding (362% and 351%, respectively).
Thus these amino acid residues probably do not make direct
interactions with the ligand, but their importance may be in
the stabilization of the ligand-receptor complex. We suggest
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Fig. 3. Ligand-dependent protection of the LBDs of wild-type and mutated hVDRs against partial proteolytic digestion with trypsin. L-
[35S]Methionine-labeled wild-type and mutated hVDRs were pre-incubated with 1 WM calcitriol (a) or MC1288 (b) at 22‡C before exposing
them to partial proteolytic digestion with trypsin (25 Wg/ml).
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that calcitriol is positioned in the ligand binding pocket sim-
ilarly to all-trans retinoic acid with its A-ring at the bottom of
the ligand binding cavity.
To ensure that the decreased binding a⁄nities of His229A-
la, Asp232Ala, Tyr236Ala, Ser237Ala, and Ser275Ala substi-
tuted hVDRs are not due to a di¡erential folding of the mu-
tated receptors compared with the wild-type receptor we
repeated the binding and conformational analyses of these
hVDRs with the synthetic vitamin D analog MC1288. From
Fig. 2b it can be seen that the point mutations did not mark-
edly in£uence the binding of MC1288 to the mutated hVDRs
compared with that of the wild-type receptor. After partial
proteolytic digestion by trypsin the digestion patterns of
Tyr236Ala, Ser237Ala, and Ser275Ala substituted hVDRs
were similar with that of the wild-type receptor indicating
that these point mutations had not in£uenced the folding of
the receptor. The digestion pattern of His229Ala substituted
receptor was slightly di¡erent from that of the wild-type re-
ceptor suggesting that this mutation had changed the folding
of the receptor to some extent. In addition, even though the
digestion pattern of the Asp232Ala substituted receptor was
similar to that of the wild-type receptor, the intensity of the
LBD was less than that of the wild-type receptor, suggesting
that also this mutation had slightly changed the folding of the
receptor. Therefore we cannot exclude the possibility that the
decreased a⁄nity of calcitriol to these receptors is due to
di¡erent conformations of these receptors.
Our results also suggest that MC1288 and calcitriol have
somewhat di¡erent binding sites in the putative helices 3 and 5
of hVDR. While Liu et al. have recently reported that
MC1288 has di¡erent binding requirements in helices 11
and 12 of hVDR from that of calcitriol [12], it is interesting
to notice that MC1288 may have di¡erent overall binding
requirements compared with calcitriol, even though their
only structural di¡erence is the 20-epi bond.
We have demonstrated here that the putative helix 3 of
hVDR and, especially, the central part of it, is important
for the binding of calcitriol to its receptor. In addition, helix
5 seems to participate in the binding process. We suggest that
the amino acid residues His229, Asp232, and Ser237 may act
as contact sites between calcitriol and hVDR. We further
suggest that Tyr236 and Ser275 may also have important roles
in ligand binding, e.g. by stabilizing the ligand-receptor com-
plex. To our knowledge this is the ¢rst report demonstrating
speci¢c contact sites of calcitriol in the putative helices 3 and 5
of hVDR.
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